John Öhd,
• Positive topline data from our Phase 1b lipopolysaccharide (LPS) provocation study.
• Submitting a patent application based on new data for the use of sevuparin, in kidney disease and anemia, a significant new market opportunity.
• Securing access to bridge financing of up to
I am looking forward to an exciting 2023 as the enhanced communication of our science and data will further highlight the potential of sevuparin to all of our key stakeholders and potential partners.”
The first quarter in figures
- The loss after tax amounted to TSEK 6 040 (3 065).
- The loss per share amounted to
SEK 0,38 (0,19). - The cash flow from current operations was negative in the amount of TSEK 6 335 (7 545).
Important events during the first quarter
Modus Therapeutics submits patent application for sevuparin in kidney disease.Modus Therapeutics announces positive topline data from its Phase 1b LPS provocation study evaluating the potential of sevuparin for treatment of sepsis.Modus Therapeutics participated in BIO-Europe spring,Basel .Modus Therapeutics secures access to bridge financing (subject of approval at the AGM 11 May, 2023).
Important events after the end of the period
Modus Therapeutics participated in LSX,London .
CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid today
© Modular Finance, source